Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07090148 · ClinicalTrials.gov registry record · Phase 1

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

A Phase 1 study of Recurrent Prostate Cancer and Oligometastatic Prostate Cancer (OMPC), sponsored by University of Wisconsin, Madison.

Recruiting
Registry status
Phase 1
Development phase
14
Enrollment target
1
Study location

NCT07090148 is a Phase 1 study of Recurrent Prostate Cancer and Oligometastatic Prostate Cancer (OMPC) that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 14 participants, below the 138-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07090148, a Phase 1 study of Recurrent Prostate Cancer and Oligometastatic Prostate Cancer (OMPC), is actively recruiting participants, sponsored by University of Wisconsin, Madison.

RECRUITING
Registry status
Phase 1
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn whether an experimental vaccine called pTVG-HP ("vaccine" or "DNA vaccine"), combined with a drug called nivolumab can increase the cancer-fighting ability of a person's immune cells. The main question it aims to answer is whether the combination of medicines can get rid of metastatic tumors in participants with non-castrate, recurrent, oligometastatic prostate cancer. Participants will undergo: * Treatment with pTVG-HP * Treatment with Nivolumab * Radiation Therapy

Conditions Studied

Recurrent Prostate Cancer Oligometastatic Prostate Cancer (OMPC) Prostate Cancer Patients Non-castrate Prostate Cancer

Interventions

  • DRUG Anti-PD-1 monoclonal antibody
  • BIOLOGICAL pTVG-HP DNA vaccine

Study Locations (1)

Wisconsin

  • University of Wisconsin - Madison - Madison

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2026-03-03
Est. Completion 2030-10
Phase Phase 1

Sponsor

University of Wisconsin, Madison

1,039 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07090148

The ClinicalTrials.gov registry entry for NCT07090148 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 138-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (90% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Recurrent Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Anti-PD-1 monoclonal antibody is the first listed.

NCT07090148 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT07090148 about?

NCT07090148 is a clinical study titled "Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC". The goal of this clinical trial is to learn whether an experimental vaccine called pTVG-HP ("vaccine" or "DNA vaccine"), combined with a drug called nivolumab can increase the cancer-fighting ability of a person's immune cells. The main question it aims to answer is whether the combination of medic...

What is the current status of trial NCT07090148?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2026-03-03. Estimated completion is 2030-10.

What conditions does trial NCT07090148 study?

This clinical trial studies the following conditions: Recurrent Prostate Cancer, Oligometastatic Prostate Cancer (OMPC), Prostate Cancer Patients, Non-castrate Prostate Cancer.

What interventions are being tested in trial NCT07090148?

The interventions under investigation include: Anti-PD-1 monoclonal antibody (DRUG), pTVG-HP DNA vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT07090148?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07090148 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Prostate Cancer

All registered trials for this condition

Oligometastatic Prostate Cancer (OMPC)

All registered trials for this condition

Wisconsin

All trials with a study site in Wisconsin

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.